羟基喜树碱、奥沙利铂和卡培他滨联合治疗晚期胃癌的临床观察

目的　探讨羟基喜树碱、奥沙利铂和卡培他滨三药联合（ＨＯＸ方案）治疗晚期胃癌的疗效和毒副反应。方法　２００７年１０月至２００９年１０月我科对４８例晚期胃癌患者采用ＨＯＸ方案治疗，具体为：羟基喜树碱６ｍｇ／ｍ２静滴，ｄ１～ｄ５；奥沙利铂１００ｍｇ／ｍ２静滴，ｄ１；卡培他滨１２５０ｍｇ／ｍ２分２次口服，ｄ１～ｄ１４；２１天为１周期。每２个周期按ＲＥＣＩＣＴ１.０标准评价疗效，每周期按ＣＴＣＡＥ３.０标准评价毒副反应。结果　全组４８例均可评价疗效和毒副反应。其中，获ＣＲ５例，ＰＲ２６例，ＳＤ１４例，总有效率为６４.６％（３１／４８），疾病控制率９３.８％（４５／４８）；１年生存率为４８％，中位生存期８５个月。主要毒副反应为骨髓抑制、手足综合征以及周围神经毒性，大多为１～２级，未发生治疗相关性死亡。结论　ＨＯＸ方案治疗晚期胃癌的疗效较好，不良反应轻，值得进一步临床观察应用。

Clinical observation of hydroxycamptothecin combined with oxaliplatin and capecitabine in the treatment of advanced gastric cancer

Objective To explore the efficacy and toxicity of hydroxycamptothecin(HCPT) combined with oxaliplatin and capecitabine(HOX regimen) in treatment of patients with advanced gastric cancer.Methods Forty eight cases with advanced gastric cancer enrolled from October 2007 to October 2009 were administrated with HOX regimen,including HCPT 6mg/m2 iv d1-d5,oxaliplatin 100mg/m2 iv d1 and capecitabine 1250mg/m2 orally bid d1-d14.Twenty-one days was a cycle.The efficacy was evaluated every 2 cycles according to RECICT...